First Participant Randomized in Europe in AskBio Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Hea…
Newsrooms
TME Pharma Announces Collaboration with aimed analytics for AI-Driven Drug Discovery and Optimization
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel thera…
VelaLabs Announces Strategic Partnership with EarlyHealth Group to Support Biological Drugs Development
VelaLabs GmbH, a leading provider of analytical and quality services for biopharmaceutical development, has signed a Mem…
Common cough syrup ingredient shows promise in treating serious lung disease
Lung fibrosis occurs when lung tissue becomes damaged, thickened, and scarred, leading to breathing difficulties tha…
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT) (OTC MARKETS: BNXTF) (FSE: BXT), a bioscience company spec…
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidia…
Collaborative Breakthrough in Lung-on-Chip Technology
Collaborative Breakthrough in Lung-on-Chip Technology: AlveoliX, Vitrocell, University of Bern and Helmholtz Institute f…
TME PHARMA reports H1 2024 financial results and provides business and clinical update
Statistically significant survival benefit of NOX-A12 + bevacizumab + radiotherapy for glioblastoma patients compared to…
Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial
Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metas…
faCellitate GmbH Wins 1st Place in Technology Category at the Mannheim Business Start-up Award (“Mannheimer Existenzgründerwettbewerb”) MEXI 2024
faCellitate GmbH, a pioneering company in advanced cell culture technologies, has proudly secured 1st place in the prest…